PriceTargets.com logo

Champions Oncology - CSBR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 47.93%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.07 As of 04/23/2024 01:00 AM ET
▲ +0.01 (0.20%)
Get New Champions Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSBR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSBR

Analyst Price Target is $7.50
▲ +47.93% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Champions Oncology in the last 3 months. The average price target is $7.50, with a high forecast of $7.50 and a low forecast of $7.50. The average price target represents a 47.93% upside from the last price of $5.07.

This chart shows the closing price for CSBR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Champions Oncology. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2024Craig HallumReiterated RatingBuy ➝ HoldN/A
9/22/2023Roth MkmLower TargetBuy ➝ Buy$9.00 ➝ $7.50N/A
3/16/2023BenchmarkDowngradeBuy ➝ HoldN/A
12/14/2022Craig HallumLower Target$12.00N/A
8/3/2021Roth CapitalReiterated RatingBuyLow
3/15/2021Roth CapitalBoost TargetBuy$13.50 ➝ $16.00High
11/27/2019BenchmarkInitiated CoverageBuy$11.00Medium
11/18/2019BenchmarkInitiated CoverageBuy$11.00High
9/20/2019Roth CapitalInitiated CoverageBuy$9.25Low
7/24/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 6 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 21 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 55 very positive mentions
  • 26 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
3/25/2024
  • 63 very positive mentions
  • 24 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 63 very positive mentions
  • 24 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Champions Oncology logo
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Read More

Today's Range

Now: $5.07
Low: $5.03
High: $5.07

50 Day Range

MA: $10.15
Low: $9.11
High: $10.96

52 Week Range

Now: $5.07
Low: $7.19
High: $14.68

Volume

2,321 shs

Average Volume

2,386 shs

Market Capitalization

$68.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Champions Oncology?

The following Wall Street research analysts have issued reports on Champions Oncology in the last twelve months: Craig Hallum, and Roth Mkm.
View the latest analyst ratings for CSBR.

What is the current price target for Champions Oncology?

1 Wall Street analysts have set twelve-month price targets for Champions Oncology in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 47.9%. Roth Mkm has the highest price target set, predicting CSBR will reach $7.50 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $7.50 for Champions Oncology in the next year.
View the latest price targets for CSBR.

What is the current consensus analyst rating for Champions Oncology?

Champions Oncology currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CSBR.

What other companies compete with Champions Oncology?

Other companies that are similar to Champions Oncology include Precision BioSciences, Turnstone Biologics, Gritstone bio, Elutia and Instil Bio. Learn More about companies similar to Champions Oncology.

How do I contact Champions Oncology's investor relations team?

Champions Oncology's physical mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company's listed phone number is (201) 808-8400 and its investor relations email address is [email protected]. The official website for Champions Oncology is www.championsoncology.com. Learn More about contacing Champions Oncology investor relations.